中国药师
中國藥師
중국약사
China Pharmacist
2015年
10期
1685-1688,1728
,共5页
王欣晨%商玉萍%邓芳%蔡颖%张小丹%潘春晓
王訢晨%商玉萍%鄧芳%蔡穎%張小丹%潘春曉
왕흔신%상옥평%산방%채영%장소단%반춘효
互为内标法%紫杉醇%多西紫杉醇%治疗药物监测
互為內標法%紫杉醇%多西紫杉醇%治療藥物鑑測
호위내표법%자삼순%다서자삼순%치료약물감측
Crossing internal standard method%Paclitaxel%Docetaxel%Therapeutic drug monitoring
目的:建立高效液相色谱( HPLC)法测定人血浆中紫杉醇、多西紫杉醇浓度为临床个体化给药方案、疗效及不良反应评价提供实验依据. 方法:紫杉醇和多西紫杉醇互为内标,血浆样品采用乙腈提取法,以DikMA Diamonsil C18反相色谱柱分离样品,流动相为乙腈:水(55:45),检测波长为227 nm,流速为1. 2 ml·min-1,柱温为25℃. 结果:紫杉醇和多西紫杉醇血药浓度在0. 078~10. 0 mg · L-1范围内线性关系良好;最低定量下限为0. 039 mg · L-1;平均方法回收率分别为99. 85%和100. 35%;日内、日间相对标准差均低于5%;短期稳定性、长期稳定性和反复冻融稳定性相对标准差均低于10%. 紫杉醇临床样本血浆药物浓度监测结果范围为0. 18~6. 16 mg·L-1 ,临床监测结果存在明显个体差异. 结论:紫杉醇和多西紫杉醇血浆药物浓度差异明显,进行两药治疗药物监测十分必要. 本方法灵敏、准确、便捷、快速,适用于紫杉醇和多西紫杉醇的临床常规治疗药物监测及药动学研究.
目的:建立高效液相色譜( HPLC)法測定人血漿中紫杉醇、多西紫杉醇濃度為臨床箇體化給藥方案、療效及不良反應評價提供實驗依據. 方法:紫杉醇和多西紫杉醇互為內標,血漿樣品採用乙腈提取法,以DikMA Diamonsil C18反相色譜柱分離樣品,流動相為乙腈:水(55:45),檢測波長為227 nm,流速為1. 2 ml·min-1,柱溫為25℃. 結果:紫杉醇和多西紫杉醇血藥濃度在0. 078~10. 0 mg · L-1範圍內線性關繫良好;最低定量下限為0. 039 mg · L-1;平均方法迴收率分彆為99. 85%和100. 35%;日內、日間相對標準差均低于5%;短期穩定性、長期穩定性和反複凍融穩定性相對標準差均低于10%. 紫杉醇臨床樣本血漿藥物濃度鑑測結果範圍為0. 18~6. 16 mg·L-1 ,臨床鑑測結果存在明顯箇體差異. 結論:紫杉醇和多西紫杉醇血漿藥物濃度差異明顯,進行兩藥治療藥物鑑測十分必要. 本方法靈敏、準確、便捷、快速,適用于紫杉醇和多西紫杉醇的臨床常規治療藥物鑑測及藥動學研究.
목적:건립고효액상색보( HPLC)법측정인혈장중자삼순、다서자삼순농도위림상개체화급약방안、료효급불량반응평개제공실험의거. 방법:자삼순화다서자삼순호위내표,혈장양품채용을정제취법,이DikMA Diamonsil C18반상색보주분리양품,류동상위을정:수(55:45),검측파장위227 nm,류속위1. 2 ml·min-1,주온위25℃. 결과:자삼순화다서자삼순혈약농도재0. 078~10. 0 mg · L-1범위내선성관계량호;최저정량하한위0. 039 mg · L-1;평균방법회수솔분별위99. 85%화100. 35%;일내、일간상대표준차균저우5%;단기은정성、장기은정성화반복동융은정성상대표준차균저우10%. 자삼순림상양본혈장약물농도감측결과범위위0. 18~6. 16 mg·L-1 ,림상감측결과존재명현개체차이. 결론:자삼순화다서자삼순혈장약물농도차이명현,진행량약치료약물감측십분필요. 본방법령민、준학、편첩、쾌속,괄용우자삼순화다서자삼순적림상상규치료약물감측급약동학연구.
Objective:To establish an HPLC method for the determination of paclitaxel and docetaxel in plasma to provide refer-ence for the individualized treatment regimen and the evaluation of curative effect and adverse reactions. Methods:Paclitaxel and do-cetaxel were used as the internal standard for each other. The samples were precipitated by acetonitrile and separated on a DikMA Dia-monsil C18 column with a mixture of acetonitrile-water (55: 45) as the mobile phase. The flow rate was 1. 2 ml·min-1 . The column temperature was set at 25℃. Paclitaxel and docetaxel were detected by UV-detection (λ= 227 nm). Results: A linearity was ob-tained within the range of 0. 078-10. 0 mg·L-1 for paclitaxel and docetaxel. The limit of quantitation was 0. 039 mg·L-1 . The aver-age recovery of paclitaxel and docetaxel was 99. 85% and 100. 35%, respectively. The inter- and intra-day RSD were both less than 5% and the RSD for freeze-thaw stability was below 10%. The plasma concentration of paclitaxel in clinical samples was within the range of 0. 18-6. 16 mg·L-1 and obvious individual difference was shown. Conclusion:Therapeutic drug monitoring is very important due to the obvious differences in plasma concentration of paclitaxel and docetaxel. The established method is sensitive, accurate, con-venient and rapid in r the therapeutic drug monitoring, and is useful for the adverse drug reactions monitoring and pharmacokinetic study.
